Zobrazeno 1 - 10
of 28
pro vyhledávání: '"I. O. Logvinov"'
Autor:
T. A. Antipova, I. E. Deev, T. A. Gudasheva, S. V. Nikolaev, I. O. Logvinov, O. V. Serova, A. A. Gavrilenkova, P. Yu. Povarnina, A. V. Tarasiuk, Yu. V. Vakhitova, S. B. Seredenin
Publikováno v:
Pharmaceutical Chemistry Journal. 56:1568-1572
Autor:
T. A. Gudasheva, N. M. Sazonova, A. V. Tarasiuk, I. O. Logvinov, T. A. Antipova, D. M. Nikiforov, P. Yu. Povarnina, S. B. Seredenin
Publikováno v:
Doklady Biochemistry and Biophysics. 505:160-165
Publikováno v:
Pharmacokinetics and Pharmacodynamics. :36-43
Background. A dimeric dipeptide mimetic of the brain-derived neurotrophic factor loop 4, bis(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide (GSB-106), which activates TrkB, PI3K/AKT, MAPK/ERK and PLC-γ1 was created at the V. V. Zakusov Resear
Autor:
T A, Gudasheva, N M, Sazonova, A V, Tarasiuk, I O, Logvinov, T A, Antipova, D M, Nikiforov, P Yu, Povarnina, S B, Seredenin
Publikováno v:
Doklady. Biochemistry and biophysicsREFERENCES. 505(1)
The dimeric dipeptide mimetic hexamethylenediamide bis-(N-monosuccinyl-L-asparaginyl-L-asparagine) (GTS-301) was created on the basis of the structure of the exposed region of the neurotrophin-3 4th loop. The new compound, as well as the full-length
Autor:
I. O. Logvinov, A. V. Tarasyuk, S. B. Seredenin, T. A. Antipova, T. A. Gudasheva, A. G. Rebeko, S. V. Nikolaev, N. M. Sazonova
Publikováno v:
Pharmaceutical Chemistry Journal. 54:1126-1135
Previous studies at the V. V. Zakusov Science Research Institute of Pharmacology created a dimeric dipeptide mimetic of the most exposed fourth loop of nerve growth factor (NGF), bis-(N-monosuccinyl-L-glutamyl-Llysine) hexamethylenediamide (GK-2), wh
Autor:
A. G. Mezhlumyan, T. A. Antipova, T. A. Gudasheva, Anna V. Tallerova, P. Yu. Povarnina, I. O. Logvinov, S. B. Seredenin
Publikováno v:
Pharmaceutical Chemistry Journal. 54:431-434
The influence of the dimeric dipeptide mimetic of brain-derived neurotrophic factor (BDNF) bis(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide (GSB-106, dosage form) during three-day peroral administration at a dose of 0.1 mg/kg on the 1% sucro
Autor:
I. O. Logvinov, T. A. Antipova, A. N. Shumskii, P. I. Antipov, A. G. Rebeko, T. A. Gudasheva, N. M. Sazonova, A. V. Tarasyuk
Publikováno v:
Pharmaceutical Chemistry Journal. 52:704-710
Previously, a dimeric dipeptide mimetic bis-(N-monosuccinyl-L-glutamyl-L-lysine) hexamethylenediamide (GK-2) based on the β-turn of the fourth loop of nerve growth factor was prepared by us, activated TrkA, and exhibited neuroprotective activity in
Autor:
I. O. Logvinov, Armen G. Mezhlumyan, Anna V. Tallerova, Polina Povarnina, Tatiana A Gudasheva, T. A. Antipova, Yulia N. Firsova, Sergey B. Seredenin
Publikováno v:
Biomolecules
Biomolecules, Vol 11, Iss 252, p 252 (2021)
Volume 11
Issue 2
Biomolecules, Vol 11, Iss 252, p 252 (2021)
Volume 11
Issue 2
A mimetic of the BDNF loop 4, bis (N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide, named GSB-106, was designed and synthesized in our scientific group. The compound activated TrkB, MAPK/ERK, PI3K/AKT, and PLCγ in in vitro experiments. In vivo
Autor:
Polina Povarnina, I. O. Logvinov, S. V. Kruglov, Sergey B. Seredenin, Dmitry M. Nikiforov, Tatiana A. Antipova, Tatiana A Gudasheva
Publikováno v:
CNSneurological disorders drug targets. 20(10)
Background: A dimeric dipeptide mimetic of the BDNF loop 4, bis(N-monosuccinyl- L-seryl-L-lysine) hexamethylenediamide (GSB-106) activates TrkB, PI3K/AKT, MAPK/ ERK, and PLC-γ1, and was created at the V.V. Zakusov Research Institute of Pharmacology.
Autor:
S. V. Nikolaev, Tatiana A Gudasheva, S. B. Seredenin, P. Yu. Povarnina, I. O. Logvinov, T. A. Antipova
Publikováno v:
Doklady. Biochemistry and biophysics. 494(1)
Previously, we designed and synthesized dipeptide mimetics of individual loops of the nerve growth factor (NGF) and the brain-derived neurotrophic factor (BDNF). It was shown that these mimetics activate the corresponding tyrosine kinase (Trk) recept